Lambda Therapeutic acquires Biovail CRD

Ahmedabad based contract research organisation has acquired Canada based contract research firm for an undisclosed sum.

The acquired entity has been renamed as Lambda Therapeutic Research Inc. Biovail Contract Research is one of North America's oldest clinical pharmacology CROs.

Bindi Chudgar, managing director of Lambda said,"The company will now have a global infrastructure of over 600 beds dedicated to phase-1 clinical pharmacology,along with the full spectrum of clinical data management and biostatistical services.The company said in a statement that as a result of this acquisition, the annual gross revenue of Lambda across its worldwide facilities is in will be in excess of $50 million.

Lambda India, an unlisted entity, has registered a net sales close to Rs100 crore in 2009-10. With the acquisition of Biovail CRD Lambda has now established a worldwide infrastructure in India, UK, Poland and North America.

This deal has been structured as an Asset Purchase Agreement wherein Lambda will now have an independent business unit in Toronto, Ontario, consisting of two facilities with over 50,000 square feet dedicated to clinical or bioanalytical services.

These facilities house six study clinics, including a 12-bed, Phase I first-in-human unit and a total capacity of 194 beds, as well as a clinical contact centre and subject screening unit, a fully equipped bioanalytical laboratory and a full-service clinical data management department.

Lambda Canada has over 100 employees and has conducted over 3,500 Phase l, bioavailability or bioequivalence and drug-interaction studies on more than 400 different chemical entities. It has a database that exceeds 100,000 adult male and female volunteers for potential enrollment in studies.

Also the acquisition will help Lambda to have the track record of having systems that have been audited in compliance with United States Food and Drug Administration (USFDA), Therapeutic Products Directorate (Canada), European Agency for the Evaluation of Medicinal Products (EMA), and other comparable foreign regulatory bodies, thanks to Biovail.

Founded in 1999, Lambda Therapeutic Research Limited has a portfolio of clinical development services, delivered through a team of more than 400 members.

Besides being present in two locations in India, Ahmedabad and Mumbai, Lambda also has a regional office in the US and clinical operations at Poland and Canada. Lambda has completed over 1000 BA/BE studies, 20 first-in-man studies & 35 Phase II & III clinical trials.

image
Business Standard
177 22
Business Standard

Lambda Therapeutic acquires Biovail CRD

BS Reporter  |  Mumbai/ Ahmedabad 



Ahmedabad based contract research organisation has acquired Canada based contract research firm for an undisclosed sum.

The acquired entity has been renamed as Lambda Therapeutic Research Inc. Biovail Contract Research is one of North America's oldest clinical pharmacology CROs.

Bindi Chudgar, managing director of Lambda said,"The company will now have a global infrastructure of over 600 beds dedicated to phase-1 clinical pharmacology,along with the full spectrum of clinical data management and biostatistical services.The company said in a statement that as a result of this acquisition, the annual gross revenue of Lambda across its worldwide facilities is in will be in excess of $50 million.

Lambda India, an unlisted entity, has registered a net sales close to Rs100 crore in 2009-10. With the acquisition of Biovail CRD Lambda has now established a worldwide infrastructure in India, UK, Poland and North America.

This deal has been structured as an Asset Purchase Agreement wherein Lambda will now have an independent business unit in Toronto, Ontario, consisting of two facilities with over 50,000 square feet dedicated to clinical or bioanalytical services.

These facilities house six study clinics, including a 12-bed, Phase I first-in-human unit and a total capacity of 194 beds, as well as a clinical contact centre and subject screening unit, a fully equipped bioanalytical laboratory and a full-service clinical data management department.

Lambda Canada has over 100 employees and has conducted over 3,500 Phase l, bioavailability or bioequivalence and drug-interaction studies on more than 400 different chemical entities. It has a database that exceeds 100,000 adult male and female volunteers for potential enrollment in studies.

Also the acquisition will help Lambda to have the track record of having systems that have been audited in compliance with United States Food and Drug Administration (USFDA), Therapeutic Products Directorate (Canada), European Agency for the Evaluation of Medicinal Products (EMA), and other comparable foreign regulatory bodies, thanks to Biovail.

Founded in 1999, Lambda Therapeutic Research Limited has a portfolio of clinical development services, delivered through a team of more than 400 members.

Besides being present in two locations in India, Ahmedabad and Mumbai, Lambda also has a regional office in the US and clinical operations at Poland and Canada. Lambda has completed over 1000 BA/BE studies, 20 first-in-man studies & 35 Phase II & III clinical trials.

RECOMMENDED FOR YOU

Lambda Therapeutic acquires Biovail CRD

Ahmedabad based contract research organisation Lambda Therapeutic Research has acquired Canada based contract research firm Biovail CRD for an undisclosed sum.

Ahmedabad based contract research organisation has acquired Canada based contract research firm for an undisclosed sum.

The acquired entity has been renamed as Lambda Therapeutic Research Inc. Biovail Contract Research is one of North America's oldest clinical pharmacology CROs.

Bindi Chudgar, managing director of Lambda said,"The company will now have a global infrastructure of over 600 beds dedicated to phase-1 clinical pharmacology,along with the full spectrum of clinical data management and biostatistical services.The company said in a statement that as a result of this acquisition, the annual gross revenue of Lambda across its worldwide facilities is in will be in excess of $50 million.

Lambda India, an unlisted entity, has registered a net sales close to Rs100 crore in 2009-10. With the acquisition of Biovail CRD Lambda has now established a worldwide infrastructure in India, UK, Poland and North America.

This deal has been structured as an Asset Purchase Agreement wherein Lambda will now have an independent business unit in Toronto, Ontario, consisting of two facilities with over 50,000 square feet dedicated to clinical or bioanalytical services.

These facilities house six study clinics, including a 12-bed, Phase I first-in-human unit and a total capacity of 194 beds, as well as a clinical contact centre and subject screening unit, a fully equipped bioanalytical laboratory and a full-service clinical data management department.

Lambda Canada has over 100 employees and has conducted over 3,500 Phase l, bioavailability or bioequivalence and drug-interaction studies on more than 400 different chemical entities. It has a database that exceeds 100,000 adult male and female volunteers for potential enrollment in studies.

Also the acquisition will help Lambda to have the track record of having systems that have been audited in compliance with United States Food and Drug Administration (USFDA), Therapeutic Products Directorate (Canada), European Agency for the Evaluation of Medicinal Products (EMA), and other comparable foreign regulatory bodies, thanks to Biovail.

Founded in 1999, Lambda Therapeutic Research Limited has a portfolio of clinical development services, delivered through a team of more than 400 members.

Besides being present in two locations in India, Ahmedabad and Mumbai, Lambda also has a regional office in the US and clinical operations at Poland and Canada. Lambda has completed over 1000 BA/BE studies, 20 first-in-man studies & 35 Phase II & III clinical trials.

image
Business Standard
177 22
Widgets Magazine

More News

  • Monsanto approaches Delhi HC against CCI decision Monsanto approaches Delhi HC against CCI order
  • Drug pricing norms outdated, must be amended: NPPA chief Pricing norms outdated, says NPPA chief
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard